Skip to main content

Table 1 Demographic and Clinical Characteristics of Patients at Baseline

From: Pericardial effusion after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal cancer

Characteristic

No. of patients (%)

Univariate analysisaP value

Age (years)

 Median (Range)

56.5 (34–81)

 

  ≤ 56: >  56

63 (50): 63 (50)

.293

Gender

 Male: Female

121 (96.0): 5 (4.0)

.077

Body mass index

 Median (Range)

21.4 (15.5–30.0)

 

  ≤ 21.4: >  21.4

64 (50.8): 62 (49.2)

.721

Body surface area

 Median (Range)

1.65 (1.3–2.1)

 

  ≤ 1.65: >  1.65

66 (52.4): 60 (47.6)

.784

Eastern Cooperative Oncology Group performance status

 0: 1: 2: 3

12 (9.5): 98 (77.8): 15 (11.9): 1 (0.8)

.539

Stage

 I: II: III

2 (1.6): 10 (7.9): 114 (90.5)

.600

Tumor location

 U: M: L

51 (40.5): 30 (23.8): 20 (15.9)

.001

 U + M

9 (7.1)

 

 U + M + L

1 (0.8)

 

 M + L

15 (11.9)

 

Histology

 Squamous cell carcinoma

121 (96.0)

.508

 Adenocarcinoma

3 (2.4)

 

 Poorly differentiated carcinoma

2 (1.6)

 

Smoking

 Yes: No

114 (90.5): 12 (9.5)

.350

Alcohol

 Yes: No

115 (91.3): 11 (8.7)

.094

Hypertension

 Yes: No

25 (19.8): 101 (80.2)

.418

Diabetes

 Yes: No

15 (11.9): 111 (88.1)

.582

Cardiovascular disease

 Yes: No

7 (5.6): 119 (94.4)

.097

Radiation dose (Gray)

 Median (range)

61.2 (50–66.6)

 

  ≤ 60: >  60

52 (41.3): 74 (58.7)

.238

Chemotherapy regimen

 Fluoropyrimidine-based

118 (93.7)

.900

 Taxane-based

4 (3.2)

 

 Others

4 (3.2)

 
  1. Abbreviations: L lower thoracic esophagus, M middle thoracic esophagus, U upper thoracic esophagus
  2. aUnivariate analysis of patients’ characteristics associated with pericardial effusion